

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



August 20, 2025

Company Anicom Holdings, Inc.
Representative Director Nobuaki Komori
(Securities Code: 8715 TSE PRIME)
Inquiries to Norihiko Sakurai
Corporate Planning Department,
General Manager

Monthly Management Parameters, July 2025

The following is a summary of the major targets set as the management targets in Anicom Group's pet insurance business and new business initiatives aimed at realizing the vision of becoming a prevention-oriented company.

Monthly Management Parameters, FY2025 (From April 1, 2025 to March 31, 2026)

	April	May	June	July	August	September
Net premiums written (previous year)	5,134JPYmn (4,670 JPYmn)	5,424JPYmn (4,932 JPYmn)	5,220JPYmn (4,750 JPYmn)	5,175JPYmn (4,708 JPYmn)	JPYmn (4,832 JPYmn)	JPYmn (4,894 JPYmn)
No. of policies in force (previous year)	1,297,369 (1,199,358)	1,308,167 (1,206,083)	1,318,043 (1,213,737)	1,326,765 (1,220,965)	(1,228,626)	(1,236,904)
Renewal rate (previous year)	88.5% (88.2%)	88.2% (88.0%)	88.2% (88.0%)	88.4% (88.1%)	% (87.9%)	% (88.2%)
No. of applicants of Doubutsu Kenkatsu (gut microbiota testing) (previous year)	20,749 (18,886)	23,085 (21,379)	19,134 (19,166)	20,123 (18,268)	(20,018)	(19,287)
No. of patents held*1 (previous year)	22 (18)	22 (18)	23 (19)	24 (19)	(19)	(20)

	October	November	December	January	February	March
Net premiums written (previous year)	JPYmn (4,911 JPYmn)	JPYmn (4,783 JPYmn)	JPYmn (5,023 JPYmn)	JPYmn (5,181 JPYmn)	JPYmn (4,974 JPYmn)	JPYmn (5,201 JPYmn)
No. of policies in force (previous year)	(1,243,536)	(1,250,158)	(1,260,176)	(1,269,979)	(1,278,228)	(1,287,923)
Renewal rate (previous year)	% (88.5%)	% (88.4%)	% (88.1%)	% (88.2%)	% (88.3%)	% (88.7%)
No. of applicants of Doubutsu Kenkatsu (gut microbiota testing) (previous year)	(22,087)	(19,752)	(18,398)	(21,875)	(20,630)	(22,674)
No. of patents held* ¹ (previous year)	(20)	(20)	(21)	(21)	(22)	(22)

*1 We disclose the figure as a key figure related to the promotion of BioInsurTech using big data, with the aim of realizing a prevention-oriented company that prevents injuries and illnesses before they occur.

(Reference) “Monthly Management Parameters” will be disclosed after middle of each month, but it will be disclosed on the same day as the quarterly earnings announcement date for June, September, December, and March.